- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01759446
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84106
- Lifetree Clinical Research
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests.
- Subject is a recreational opioid user who is NOT dependent on opioids based on Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision (DSM IV TR) criteria. A recreational opioid user is defined as a user of opioids for non medical purposes (i.e., for psychoactive effects) on at least 10 occasions within the last year and at least once in the 12 weeks before the Screening Visit (Visit 1).
- Subjects must have experience with intranasal opioid administration, defined as intranasal use on at least 3 occasions within the last year before Screening.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
- Subject is able to speak, read, and understand English sufficiently to comprehend the nature of the study and to understand the informed consent form (ICF) and consent process.
- An informed consent document signed and dated by the subject.
Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
-
Exclusion Criteria:
- Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine), as assessed by the Investigator using the DSM IV TR criteria.
- Has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorders (excluding nicotine and caffeine).
- Has a positive urine drug screen (UDS) including tetrahydrocannabinol (THC) at Screening (Visit 1). NOTE: Subjects with an opioid positive or THC-positive UDS at Visit 1 may be re tested once on or before Visit 2 (Day 0). If the UDS re test is negative, the subject can proceed to Visit 2. A positive UDS at Visit 2 will exclude the subject from further participation, unless the UDS is THC-positive in which the subject can continue in the study at the discretion of the Investigator.
- Has a positive alcohol breath test at Screening. Positive results may be repeated and/or subjects re scheduled at the Investigator's discretion.
- Has any condition in which an opioid is contraindicated (e.g., significant respiratory depression, acute or severe bronchial asthma or hypercarbia, suspected of having paralytic ileus).
Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Comparatore placebo: Placebo taken first
Placebo powder snorted with all other arms taken crossover therafter
|
Snorted in both nostrils within 5 minutes; 48 hours washout between doses
|
Comparatore attivo: Generic H/A taken first
Generic hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
|
Snorted in both nostrils within 5 minutes; 48 hours washout between doses
|
Comparatore attivo: Vycavert taken first
Vycavert hydrocodone/APAP 10/325mg pulverized tablet snorted with all other arms taken crossover therafter
|
Snorted in both nostrils within 5 minutes; 48 hours washout between doses
|
Comparatore attivo: Generic H/A plus i taken first
Generic hydrocodone/APAP 10/325mg plus additional inactive ingredients pulverized tablet snorted with all other arms taken crossover therafter
|
Snorted in both nostrils within 5 minutes; 48 hours washout between doses
|
Comparatore attivo: Generic H/A plus p taken first
Generic hydrocodone/APAP 10/325mg plus one placebo pulverized tablet snorted with all other arms taken crossover therafter
|
Snorted in both nostrils within 5 minutes; 48 hours washout between doses
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Emax - Maximum Drug Liking
Lasso di tempo: 8 hours
|
"Do you dislike or like the drug effect you are feeling now?"
The question is scored using a 100-point bipolar visual analog scale (VAS) anchored in the center with "neither like nor dislike" (score of 50), on the left with "Strong Disliking" (score of 0) and on the right with "Strong Liking" (score of 100).
Maximum Score.
Assessment were made at 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dosing.
|
8 hours
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Lynne Webster, MD, Lifetree Clinical Research
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- AP-ADF-301
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Placebo taken first
-
NYU Langone HealthRitirato
-
University of Kansas Medical CenterNational Institute of Nursing Research (NINR); National Institutes of Health...ReclutamentoObesità pediatrica | Perdita di pesoStati Uniti
-
McGill UniversitySave the Children; European Network of Foundations Children and Violence Evaluation... e altri collaboratoriSconosciutoAbuso di minori | Relazioni genitori-figliCanada
-
Coopervision, Inc.Completato
-
Foundation for Innovative New Diagnostics, SwitzerlandMinistry of Health, Malaysia; Hospital Sultanah Bahiyah; Malaysian AIDS CouncilReclutamento
-
University of PennsylvaniaCompletatoDisturbi da Uso di Sostanze | Stigma, socialeStati Uniti
-
University Hospital, Basel, SwitzerlandLondon School of Hygiene and Tropical Medicine; Swiss National Science Foundation e altri collaboratoriAttivo, non reclutanteInfezione da virus dell'immunodeficienza umana (HIV).Lesoto, Malawi
-
Universidade Federal do ParaCompletatoIpersensibilità dentaleBrasile
-
Midatech Pharma US Inc.PharPoint Research, Inc.Terminato
-
Eunice Kennedy Shriver National Institute of Child...TerminatoObesità | Carenza di ormone della crescita | Bassa staturaStati Uniti